Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial.

"Conflicts of Interest M.F. has received research grants from AbbVie, Amgen, Biogen, EG, Janssen, Pfizer, Takeda, and Viatris; consultancy fees from AbbVie, Agomab Therapeutics, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Janssen-Cilag, Medtronic, MSD, Pfizer, Regeneron, Samsung Bioepis, Sandoz, Takeda, and Thermo Fisher; and speakers’ fees from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Dr Falk, Ferring, Janssen-Cilag, Lamepro, MSD, Pfizer, Sandoz, Takeda, Truvion Healthcare, and Viatris. P.M.I. has received speaking fees from AbbVie, Bristol Myers Squibb, Celgene, Celltrion, Falk Pharma, Ferring, Galapagos, Gilead, MSD, Janssen, Lilly, Pfizer, Takeda, Tillotts, Sapphire Medical, Sandoz, Shire, and Warner Chilcott; research grants from Celltrion, Galapagos, MSD, Pfizer, and Takeda; and advisory fees from AbbVie, Arena, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Genentech, Gilead, Hospira, Janssen, Lilly, MSD, Pfizer, Pharmacosmos, Prometheus, Roche, Sandoz, Samsung Bioepis, Takeda, Topivert, VH2, Vifor, and Warner Chilcott. M.T.A. has served as a consultant for AbbVie, Allergan, Amgen, Boehringer Ingelheim, Celgene, Cornerstones Health, Focus Medical Communications, Gilead Sciences, Imedex, Janssen Biotech, Landos, Lilly, Nestec, Pfizer, Prometheus Laboratories, Roche Pharmaceuticals, Shire, Takeda, and Vindico Medical Education. J.A. has served as a consultant for AbbVie, Janssen Pharmaceutical, and Takeda. X.G. and QC. report no conflicts of interest. T.F. has received research grants from AbbVie, Alfresa, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, EA Pharma, Eisai, Gilead, Janssen, Kissei, Lilly, Mebix, Sanofi, and Takeda; and speaking honoraria from AbbVie, Ajinomoto Pharma, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, EA Pharma, Eisai, Janssen, Kissei, Kyorin, Kyowa Hakko Kirin, Kissei Pharma, Mitsubishi Tanabe, Mochida, Nichiiko, Nippon Kayaku, Pfizer, Taiho, Takeda, and Zeria Pharma. A.R. has received speaking fees from AbbVie, Ferring, Janssen, and Takeda. J.T. has received speaker’s fees from AbbVie, Galapagos, Janssen, and Pfizer; advisory fees from AbbVie, Janssen, and Pfizer; and research grants from AbbVie and Janssen. E.N., A.S., K.W., K.K., S.B., Q.Z., and J.K. are employees of AbbVie and may own AbbVie stock or options. X.L. is a former employee of AbbVie and may own AbbVie stock or options. B.F. has received consulting fees from AbbVie, Allergan, ActoGeniX, Albireo, Amgen, AstraZeneca, Atlantic Pharma, Avaxia Biologics, Axcan, Baxter Healthcare Corp, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Centocor, Elan/Biogen, enGene, Ferring, Genentech, GICare, Gilead, Given Imaging Inc, GlaxoSmithKline, Ironwood, Johnson & Johnson/Janssen, Kyowa Hakko Kirin, Lycera, Lexicon, Lilly, Merck, Mesoblast, Millennium, Nektar, Novartis Novo Nordisk, Prometheus, Pfizer, Protagonist, Receptos, Salix, Serono, Shire, Sigmoid, Synergy, Takeda, Teva, Tillotts, TiGenix, UCB, Warner-Chilcott, Wyeth, Zealand, and Zyngenia; speaker fees from AbbVie, Johnson & Johnson/Janssen, Takeda, and UCB; financial support for research from AbbVie, Amgen, AstraZeneca/MedImmune, Atlantic Pharmaceuticals, Boehringer Ingelheim, Celgene Corporation, Celltech, Genentech Inc/Hoffmann–La Roche, Gilead, GlaxoSmithKline, Janssen Research & Development, Pfizer, Receptos/Celgene, Sanofi, Santarus, Takeda Development Center Americas, Tillotts, and UCB; and has served as a member of the board of directors of Robarts Clinical Trials, Inc. R.P. has served as a consultant for Abbott, AbbVie, Alimentiv, Amgen, Arena Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Ferring, Galapagos, Fresenius Kabi, Genentech, Gilead Sciences, Glaxo-Smith Kline, JAMP Bio, Janssen, Lilly, Merck, Mylan, Novartis, Oppilan Pharma, Organon, Pandion Pharma, Pendopharm, Pfizer, Progenity, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity Therapeutics, Takeda, Theravance Biopharma, Trellus, Viatris, and UCB. He has received speaking fees from AbbVie, Amgen, Arena Pharmaceuticals, Bristol-Myers Squibb, Celgene, Ferring, Fresenius Kabi, Gilead Sciences, Janssen, Lilly, Merck, Organon, Pfizer, Roche, Sandoz, Shire, and Takeda Pharmaceuticals; and advisory fees from AbbVie, Alimentiv, Amgen, Arena Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Ferring, Fresenius Kabi, Genentech, Gilead Sciences, Glaxo-Smith Kline, JAMP Bio, Janssen, Lilly, Merck, Mylan, Novartis, Oppilan Pharma, Organon, Pandion Pharma, Pfizer, Progenity, Protagonist, Roche, Sandoz, Shire, Sublimity Therapeutics, and Takeda."

"Funding This work was supported by AbbVie. AbbVie funded the research for this study and provided writing support. No honoraria or payments were made for authorship."

"Clinical trial registration number NCT03105102."